Announcement as per Regulation 30 of SEBI LODR Regulation 2015

Corporate Office: 1506, Chiranjiv Tower, Shivalik Rasayan Limited 43, Nehru Place, New Delhi-19 Tel: +91 11 47589500 (30 Lines), 26221811/26418182 E-Mail : info@shivalikrasayan.com Website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041 Ref: STEX/Announcement/2026-27 Date: 03.11.2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla complex Dalal Street, Bandra(E) Mumbai- 400051 Mumbai – 400001 Code No: 539148 Symbol: SHIVALIK Sub: Filed Drug Master File (DMF) Dear Sir/ Ma’am, Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that: Shivalik Rasayan Limited has successfully filed Drug Master File (DMF) for Avapritinib API with USFDA for which the Complete Assessment (CA) has been done. It is used to treat Gastrointestine Stromal Tumors (GIST). It is a product of Sanofi and is marketed under brand name of “Ayvakit”. Ayvakit achieved a revenue of 700 million USD during 2025. This is for your information and records. Thanking You Yours truly, For Shivalik Rasayan Limited Parul Choudhary Company Secretary & Compliance Officer ACS: 34854 Regd. Office & Factory: Kolhupani, P.O. Chandanwari, Dehradun-248 007. Phone: 0135-2773429, 2772038, E-mail: ddn@shivalikrasayan.com Works Dahej-II: D-2/CH/41/A, GIDC Industrial Estates, Dahej-II, Pin- 392140 Distt, Bharuch (Gujarat) R&D Centre: SP-1192 A&B, Phase-IV, Industrial Area, Bhiwadi-301019, Dist. Alwar, Bhiwadi (Rajasthan) Tel.: 07240009670